ID   IDHP_HUMAN              Reviewed;         452 AA.
AC   P48735; B2R6L6; B4DFL2; Q96GT3;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2002, sequence version 2.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Isocitrate dehydrogenase [NADP], mitochondrial;
DE            Short=IDH;
DE            EC=1.1.1.42;
DE   AltName: Full=ICD-M;
DE   AltName: Full=IDP;
DE   AltName: Full=NADP(+)-specific ICDH;
DE   AltName: Full=Oxalosuccinate decarboxylase;
DE   Flags: Precursor;
GN   Name=IDH2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RA   Huh T.-L., Oh I.-U., Kim Y.O., Huh J.-W., Song B.J.;
RL   Submitted (NOV-1992) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain cortex, Heart, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-67; LYS-106; LYS-155;
RP   LYS-166; LYS-180; LYS-256; LYS-263; LYS-272; LYS-275; LYS-282 AND
RP   LYS-442, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   ACETYLATION AT LYS-413, AND MUTAGENESIS OF LYS-413.
RX   PubMed=22416140; DOI=10.1074/jbc.M112.355206;
RA   Yu W., Dittenhafer-Reed K.E., Denu J.M.;
RT   "SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and
RT   regulates mitochondrial redox status.";
RL   J. Biol. Chem. 287:14078-14086(2012).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [11]
RP   VARIANTS GLM GLY-172; LYS-172 AND MET-172, AND CHARACTERIZATION OF
RP   VARIANTS GLM GLY-172; LYS-172 AND MET-172.
RX   PubMed=19228619; DOI=10.1056/NEJMoa0808710;
RA   Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W.,
RA   Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H.,
RA   Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E.,
RA   Vogelstein B., Bigner D.D.;
RT   "IDH1 and IDH2 mutations in gliomas.";
RL   N. Engl. J. Med. 360:765-773(2009).
RN   [12]
RP   VARIANTS D2HGA2 GLN-140 AND GLY-140.
RX   PubMed=20847235; DOI=10.1126/science.1192632;
RA   Kranendijk M., Struys E.A., van Schaftingen E., Gibson K.M.,
RA   Kanhai W.A., van der Knaap M.S., Amiel J., Buist N.R., Das A.M.,
RA   de Klerk J.B., Feigenbaum A.S., Grange D.K., Hofstede F.C., Holme E.,
RA   Kirk E.P., Korman S.H., Morava E., Morris A., Smeitink J.,
RA   Sukhai R.N., Vallance H., Jakobs C., Salomons G.S.;
RT   "IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.";
RL   Science 330:336-336(2010).
RN   [13]
RP   VARIANTS GLM LEU-158; SER-162 AND LYS-172.
RX   PubMed=25495392; DOI=10.1111/neup.12187;
RA   Koh J., Cho H., Kim H., Kim S.I., Yun S., Park C.K., Lee S.H.,
RA   Choi S.H., Park S.H.;
RT   "IDH2 mutation in gliomas including novel mutation.";
RL   Neuropathology 35:236-244(2015).
RN   [14]
RP   VARIANTS SER-172; THR-172 AND TRP-172, AND INVOLVEMENT IN DISEASE.
RX   PubMed=26161668; DOI=10.1371/journal.pone.0131998;
RA   Jin Y., Elalaf H., Watanabe M., Tamaki S., Hineno S., Matsunaga K.,
RA   Woltjen K., Kobayashi Y., Nagata S., Ikeya M., Kato T. Jr.,
RA   Okamoto T., Matsuda S., Toguchida J.;
RT   "Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem
RT   Cells in Association with Gene-Specific Histone Modifications to
RT   Cartilage- and Bone-Related Genes.";
RL   PLoS ONE 10:E0131998-E0131998(2015).
CC   -!- FUNCTION: Plays a role in intermediary metabolism and energy
CC       production. It may tightly associate or interact with the pyruvate
CC       dehydrogenase complex.
CC   -!- CATALYTIC ACTIVITY: Isocitrate + NADP(+) = 2-oxoglutarate + CO(2)
CC       + NADPH.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Note=Binds 1 Mg(2+) or Mn(2+) ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Homodimer.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P48735-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48735-2; Sequence=VSP_056278;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Acetylation at Lys-413 dramatically reduces catalytic
CC       activity. Deacetylated by SIRT3. {ECO:0000269|PubMed:22416140}.
CC   -!- DISEASE: D-2-hydroxyglutaric aciduria 2 (D2HGA2) [MIM:613657]: A
CC       neurometabolic disorder causing developmental delay, epilepsy,
CC       hypotonia, and dysmorphic features. Both a mild and a severe
CC       phenotype exist. The severe phenotype is homogeneous and is
CC       characterized by early infantile-onset epileptic encephalopathy
CC       and cardiomyopathy. The mild phenotype has a more variable
CC       clinical presentation. Diagnosis is based on the presence of an
CC       excess of D-2-hydroxyglutaric acid in the urine.
CC       {ECO:0000269|PubMed:20847235}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or
CC       malignant central nervous system neoplasms derived from glial
CC       cells. They comprise astrocytomas and glioblastoma multiforme that
CC       are derived from astrocytes, oligodendrogliomas derived from
CC       oligodendrocytes and ependymomas derived from ependymocytes.
CC       {ECO:0000269|PubMed:19228619, ECO:0000269|PubMed:25495392}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Note=enetic variations are associated with cartilaginous
CC       tumors such as enchondroma or chondrosarcoma.
CC       {ECO:0000269|PubMed:26161668}.
CC   -!- SIMILARITY: Belongs to the isocitrate and isopropylmalate
CC       dehydrogenases family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X69433; CAA49208.1; -; mRNA.
DR   EMBL; AK294148; BAG57473.1; -; mRNA.
DR   EMBL; AK312627; BAG35513.1; -; mRNA.
DR   EMBL; AK316388; BAH14759.1; -; mRNA.
DR   EMBL; AC087284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092769; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02082.1; -; Genomic_DNA.
DR   EMBL; BC009244; AAH09244.1; -; mRNA.
DR   EMBL; BC071828; AAH71828.1; -; mRNA.
DR   CCDS; CCDS10359.1; -. [P48735-1]
DR   CCDS; CCDS76792.1; -. [P48735-2]
DR   PIR; S57499; S57499.
DR   RefSeq; NP_001276839.1; NM_001289910.1. [P48735-2]
DR   RefSeq; NP_001277043.1; NM_001290114.1.
DR   RefSeq; NP_002159.2; NM_002168.3. [P48735-1]
DR   UniGene; Hs.596461; -.
DR   PDB; 4JA8; X-ray; 1.55 A; A/B=41-452.
DR   PDB; 5GIS; X-ray; 1.93 A; C=165-180.
DR   PDB; 5I95; X-ray; 1.54 A; A=40-452.
DR   PDB; 5I96; X-ray; 1.55 A; A/B=1-452.
DR   PDB; 5SVN; X-ray; 2.10 A; A/B=40-452.
DR   PDB; 5SVO; X-ray; 1.87 A; A/B=40-452.
DR   PDBsum; 4JA8; -.
DR   PDBsum; 5GIS; -.
DR   PDBsum; 5I95; -.
DR   PDBsum; 5I96; -.
DR   PDBsum; 5SVN; -.
DR   PDBsum; 5SVO; -.
DR   ProteinModelPortal; P48735; -.
DR   SMR; P48735; -.
DR   BioGrid; 109644; 19.
DR   DIP; DIP-61416N; -.
DR   IntAct; P48735; 7.
DR   MINT; MINT-3016964; -.
DR   STRING; 9606.ENSP00000331897; -.
DR   BindingDB; P48735; -.
DR   DrugBank; DB01727; Isocitric Acid.
DR   iPTMnet; P48735; -.
DR   PhosphoSitePlus; P48735; -.
DR   SwissPalm; P48735; -.
DR   BioMuta; IDH2; -.
DR   DMDM; 20141568; -.
DR   OGP; P48735; -.
DR   UCD-2DPAGE; P48735; -.
DR   EPD; P48735; -.
DR   MaxQB; P48735; -.
DR   PaxDb; P48735; -.
DR   PeptideAtlas; P48735; -.
DR   PRIDE; P48735; -.
DR   DNASU; 3418; -.
DR   Ensembl; ENST00000330062; ENSP00000331897; ENSG00000182054. [P48735-1]
DR   Ensembl; ENST00000540499; ENSP00000446147; ENSG00000182054. [P48735-2]
DR   GeneID; 3418; -.
DR   KEGG; hsa:3418; -.
DR   UCSC; uc002box.4; human. [P48735-1]
DR   CTD; 3418; -.
DR   DisGeNET; 3418; -.
DR   GeneCards; IDH2; -.
DR   HGNC; HGNC:5383; IDH2.
DR   HPA; HPA007831; -.
DR   MalaCards; IDH2; -.
DR   MIM; 137800; phenotype.
DR   MIM; 147650; gene.
DR   MIM; 613657; phenotype.
DR   neXtProt; NX_P48735; -.
DR   OpenTargets; ENSG00000182054; -.
DR   Orphanet; 251589; Anaplastic astrocytoma.
DR   Orphanet; 251663; Anaplastic oligoastrocytoma.
DR   Orphanet; 251630; Anaplastic oligodendroglioma.
DR   Orphanet; 79315; D-2-hydroxyglutaric aciduria.
DR   Orphanet; 296; Enchondromatosis.
DR   Orphanet; 251601; Fibrillary astrocytoma.
DR   Orphanet; 251604; Gemistocytic astrocytoma.
DR   Orphanet; 163634; Maffucci syndrome.
DR   Orphanet; 251656; Oligoastrocytoma.
DR   Orphanet; 251627; Oligodendroglioma.
DR   Orphanet; 251598; Protoplasmic astrocytoma.
DR   PharmGKB; PA29631; -.
DR   eggNOG; KOG1526; Eukaryota.
DR   eggNOG; COG0538; LUCA.
DR   GeneTree; ENSGT00390000012547; -.
DR   HOGENOM; HOG000019858; -.
DR   HOVERGEN; HBG006119; -.
DR   InParanoid; P48735; -.
DR   KO; K00031; -.
DR   OMA; GSGPKEW; -.
DR   OrthoDB; EOG091G06IY; -.
DR   PhylomeDB; P48735; -.
DR   TreeFam; TF300428; -.
DR   BioCyc; MetaCyc:HS00021-MONOMER; -.
DR   BRENDA; 1.1.1.42; 2681.
DR   Reactome; R-HSA-71403; Citric acid cycle (TCA cycle).
DR   SIGNOR; P48735; -.
DR   ChiTaRS; IDH2; human.
DR   GeneWiki; IDH2; -.
DR   GenomeRNAi; 3418; -.
DR   PRO; PR:P48735; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000182054; -.
DR   CleanEx; HS_IDH2; -.
DR   ExpressionAtlas; P48735; baseline and differential.
DR   Genevisible; P48735; HS.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005777; C:peroxisome; IEA:Ensembl.
DR   GO; GO:0004450; F:isocitrate dehydrogenase (NADP+) activity; IDA:CACAO.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0051287; F:NAD binding; IEA:InterPro.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; ISS:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0006097; P:glyoxylate cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006102; P:isocitrate metabolic process; ISS:UniProtKB.
DR   GO; GO:0006741; P:NADP biosynthetic process; IEA:Ensembl.
DR   GO; GO:1903976; P:negative regulation of glial cell migration; IEA:Ensembl.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:1904465; P:negative regulation of matrix metallopeptidase secretion; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; TAS:Reactome.
DR   InterPro; IPR019818; IsoCit/isopropylmalate_DH_CS.
DR   InterPro; IPR004790; Isocitrate_DH_NADP.
DR   InterPro; IPR024084; IsoPropMal-DH-like_dom.
DR   PANTHER; PTHR11822; PTHR11822; 1.
DR   Pfam; PF00180; Iso_dh; 1.
DR   PIRSF; PIRSF000108; IDH_NADP; 1.
DR   SMART; SM01329; Iso_dh; 1.
DR   TIGRFAMs; TIGR00127; nadp_idh_euk; 1.
DR   PROSITE; PS00470; IDH_IMDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Glyoxylate bypass; Magnesium; Manganese;
KW   Metal-binding; Mitochondrion; NADP; Oxidoreductase;
KW   Reference proteome; Transit peptide; Tricarboxylic acid cycle.
FT   TRANSIT       1     39       Mitochondrion. {ECO:0000250}.
FT   CHAIN        40    452       Isocitrate dehydrogenase [NADP],
FT                                mitochondrial.
FT                                /FTId=PRO_0000014420.
FT   NP_BIND     115    117       NADP. {ECO:0000250}.
FT   NP_BIND     349    354       NADP. {ECO:0000250}.
FT   REGION      134    140       Substrate binding. {ECO:0000250}.
FT   METAL       291    291       Magnesium or manganese. {ECO:0000250}.
FT   METAL       314    314       Magnesium or manganese. {ECO:0000250}.
FT   BINDING     117    117       Substrate. {ECO:0000250}.
FT   BINDING     122    122       NADP. {ECO:0000250}.
FT   BINDING     149    149       Substrate. {ECO:0000250}.
FT   BINDING     172    172       Substrate. {ECO:0000250}.
FT   BINDING     299    299       NADP. {ECO:0000250}.
FT   BINDING     367    367       NADP; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000250}.
FT   SITE        179    179       Critical for catalysis. {ECO:0000250}.
FT   SITE        251    251       Critical for catalysis. {ECO:0000250}.
FT   MOD_RES      45     45       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES      48     48       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES      67     67       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      69     69       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES      80     80       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES      80     80       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     106    106       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     106    106       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     155    155       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     166    166       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     166    166       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     180    180       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     180    180       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     193    193       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     193    193       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     199    199       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     256    256       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     256    256       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     263    263       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     272    272       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     275    275       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     280    280       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     282    282       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     282    282       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     384    384       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     384    384       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     400    400       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P54071}.
FT   MOD_RES     413    413       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:22416140}.
FT   MOD_RES     442    442       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ       1     52       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056278.
FT   VARIANT     140    140       R -> G (in D2HGA2; dbSNP:rs267606870).
FT                                {ECO:0000269|PubMed:20847235}.
FT                                /FTId=VAR_065174.
FT   VARIANT     140    140       R -> Q (in D2HGA2; dbSNP:rs121913502).
FT                                {ECO:0000269|PubMed:20847235}.
FT                                /FTId=VAR_065175.
FT   VARIANT     158    158       P -> L (in GLM; somatic mutation).
FT                                {ECO:0000269|PubMed:25495392}.
FT                                /FTId=VAR_073181.
FT   VARIANT     162    162       P -> S (in GLM; somatic mutation).
FT                                {ECO:0000269|PubMed:25495392}.
FT                                /FTId=VAR_073182.
FT   VARIANT     172    172       R -> G (in GLM; somatic mutation; reduces
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:19228619}.
FT                                /FTId=VAR_073183.
FT   VARIANT     172    172       R -> K (in GLM; somatic mutation; reduces
FT                                enzymatic activity; dbSNP:rs121913503).
FT                                {ECO:0000269|PubMed:19228619,
FT                                ECO:0000269|PubMed:25495392}.
FT                                /FTId=VAR_073184.
FT   VARIANT     172    172       R -> M (in GLM; somatic mutation; reduces
FT                                enzymatic activity).
FT                                {ECO:0000269|PubMed:19228619}.
FT                                /FTId=VAR_073185.
FT   VARIANT     172    172       R -> S (found in patients with
FT                                cartilagenous tumors).
FT                                {ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_076512.
FT   VARIANT     172    172       R -> T (found in patients with
FT                                cartilagenous tumors).
FT                                {ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_076513.
FT   VARIANT     172    172       R -> W (found in patients with
FT                                cartilagenous tumors).
FT                                {ECO:0000269|PubMed:26161668}.
FT                                /FTId=VAR_076514.
FT   MUTAGEN     413    413       K->A: 44-fold loss in activity.
FT                                {ECO:0000269|PubMed:22416140}.
FT   MUTAGEN     413    413       K->Q: 20-fold decrease in Vmax.
FT                                {ECO:0000269|PubMed:22416140}.
FT   MUTAGEN     413    413       K->R: No appreciable difference in Km for
FT                                isocitrate and NADP.
FT                                {ECO:0000269|PubMed:22416140}.
FT   CONFLICT     34     34       Q -> H (in Ref. 1; CAA49208).
FT                                {ECO:0000305}.
FT   CONFLICT    435    435       T -> M (in Ref. 1; CAA49208).
FT                                {ECO:0000305}.
FT   STRAND       50     54       {ECO:0000244|PDB:5I95}.
FT   HELIX        57     69       {ECO:0000244|PDB:5I95}.
FT   TURN         70     74       {ECO:0000244|PDB:5I95}.
FT   STRAND       79     83       {ECO:0000244|PDB:5I95}.
FT   HELIX        86     91       {ECO:0000244|PDB:5I95}.
FT   TURN         92     94       {ECO:0000244|PDB:5I95}.
FT   HELIX        95    107       {ECO:0000244|PDB:5I95}.
FT   STRAND      108    112       {ECO:0000244|PDB:5I95}.
FT   HELIX       120    126       {ECO:0000244|PDB:5I95}.
FT   HELIX       135    143       {ECO:0000244|PDB:5I95}.
FT   STRAND      146    151       {ECO:0000244|PDB:5I95}.
FT   STRAND      169    173       {ECO:0000244|PDB:5I95}.
FT   HELIX       177    180       {ECO:0000244|PDB:5I95}.
FT   STRAND      182    186       {ECO:0000244|PDB:5I95}.
FT   STRAND      190    196       {ECO:0000244|PDB:5I95}.
FT   STRAND      205    214       {ECO:0000244|PDB:5I95}.
FT   STRAND      216    220       {ECO:0000244|PDB:5I95}.
FT   HELIX       225    242       {ECO:0000244|PDB:5I95}.
FT   STRAND      246    250       {ECO:0000244|PDB:5I95}.
FT   TURN        252    254       {ECO:0000244|PDB:5I95}.
FT   HELIX       258    273       {ECO:0000244|PDB:5I95}.
FT   HELIX       275    280       {ECO:0000244|PDB:5I95}.
FT   STRAND      285    289       {ECO:0000244|PDB:5I95}.
FT   HELIX       290    299       {ECO:0000244|PDB:5I95}.
FT   STRAND      304    308       {ECO:0000244|PDB:5I95}.
FT   HELIX       310    324       {ECO:0000244|PDB:5I95}.
FT   STRAND      329    335       {ECO:0000244|PDB:5I95}.
FT   STRAND      342    345       {ECO:0000244|PDB:5I95}.
FT   HELIX       352    359       {ECO:0000244|PDB:5I95}.
FT   HELIX       369    386       {ECO:0000244|PDB:5I95}.
FT   HELIX       389    407       {ECO:0000244|PDB:5I95}.
FT   HELIX       413    420       {ECO:0000244|PDB:5I95}.
FT   HELIX       422    424       {ECO:0000244|PDB:5I95}.
FT   TURN        427    429       {ECO:0000244|PDB:5I95}.
FT   HELIX       434    449       {ECO:0000244|PDB:5I95}.
SQ   SEQUENCE   452 AA;  50909 MW;  4DDC830AFC06AB52 CRC64;
     MAGYLRVVRS LCRASGSRPA WAPAALTAPT SQEQPRRHYA DKRIKVAKPV VEMDGDEMTR
     IIWQFIKEKL ILPHVDIQLK YFDLGLPNRD QTDDQVTIDS ALATQKYSVA VKCATITPDE
     ARVEEFKLKK MWKSPNGTIR NILGGTVFRE PIICKNIPRL VPGWTKPITI GRHAHGDQYK
     ATDFVADRAG TFKMVFTPKD GSGVKEWEVY NFPAGGVGMG MYNTDESISG FAHSCFQYAI
     QKKWPLYMST KNTILKAYDG RFKDIFQEIF DKHYKTDFDK NKIWYEHRLI DDMVAQVLKS
     SGGFVWACKN YDGDVQSDIL AQGFGSLGLM TSVLVCPDGK TIEAEAAHGT VTRHYREHQK
     GRPTSTNPIA SIFAWTRGLE HRGKLDGNQD LIRFAQMLEK VCVETVESGA MTKDLAGCIH
     GLSNVKLNEH FLNTTDFLDT IKSNLDRALG RQ
//
